Stock listing
TASE:CANF Can-Fite BioPharma Ltd. מניה
Home listing (TASE) of Can-Fite BioPharma Ltd.
Follow Can-Fite BioPharma Ltd. into a list and get an email when it puts out news.
Share price · TASE:CANF
268.70 ILA (agorot) +13.70 (+5.4%)
Close on Nov 19, 2026
- Day range
- 268.70 – 268.70 ILA (agorot)Nov 19, 2026
- Market cap
- 16.29M ILSAt the close on Nov 19, 2026 · price × 6.06M shares outstanding
- Traded on an average day
- 66,496 ILSMedian day 8,571 shares · 1 day with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:CANF · Home | 268.70 ILA (agorot) | +13.70 (+5.4%) | — | 268.70 | 268.70 | 268.70 | 255.00 | Close on Nov 19, 2026 |
| NYSE American:CANF | $1.435 USD | -0.034 (-2.3%) | 16,823 | $1.48 | $1.533 | $1.42 | $1.469 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:CANF · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 268.70 | +13.70 | +5.4% | 268.70 | 268.70 | 268.70 | 0 | |
| 255.00 | +5.30 | +2.1% | 258.50 | 275.00 | 250.00 | 14,211 | |
| 249.70 | -1.30 | -0.5% | 251.10 | 265.00 | 244.00 | 39,825 | |
| 251.00 | +0.90 | +0.4% | 258.90 | 262.90 | 250.00 | 30,825 | |
| 250.10 | -12.90 | -4.9% | 257.00 | 275.00 | 250.00 | 36,891 | |
| 263.00 | -16.70 | -6.0% | 270.70 | 279.20 | 257.30 | 8,779 | |
| 279.70 | +9.80 | +3.6% | 271.60 | 283.30 | 263.00 | 2,983 | |
| 269.90 | -10.10 | -3.6% | 280.00 | 284.50 | 261.00 | 11,910 | |
| 280.00 | +20.00 | +7.7% | 271.10 | 280.00 | 258.00 | 3,425 | |
| 260.00 | 0.00 | 0.0% | 256.30 | 285.00 | 256.30 | 13,474 | |
| 260.00 | -2.00 | -0.8% | 268.90 | 268.90 | 250.10 | 28,314 | |
| 262.00 | -8.50 | -3.1% | 275.00 | 285.00 | 260.50 | 11,213 | |
| 270.50 | +7.20 | +2.7% | 263.30 | 282.90 | 260.00 | 34,110 | |
| 263.30 | +6.30 | +2.5% | 262.90 | 264.10 | 256.00 | 4,670 | |
| 257.00 | -12.40 | -4.6% | 263.90 | 266.00 | 257.00 | 4,877 | |
| 269.40 | +1.40 | +0.5% | 278.90 | 281.40 | 260.60 | 10,900 | |
| 268.00 | -36.60 | -12.0% | 293.00 | 325.00 | 257.30 | 127,772 | |
| 304.60 | -3.90 | -1.3% | 303.30 | 304.60 | 295.50 | 5,936 | |
| 308.50 | +9.50 | +3.2% | 306.00 | 308.50 | 298.60 | 6,383 | |
| 299.00 | -1.20 | -0.4% | 305.00 | 309.40 | 299.00 | 426 | |
| 300.20 | -5.40 | -1.8% | 310.00 | 310.00 | 300.20 | 2,000 | |
| 305.60 | -1.40 | -0.5% | 313.50 | 313.50 | 299.00 | 16,358 | |
| 307.00 | -4.90 | -1.6% | 305.60 | 314.80 | 300.00 | 3,965 | |
| 311.90 | +2.10 | +0.7% | 306.80 | 319.60 | 300.00 | 2,389 | |
| 309.80 | +2.20 | +0.7% | 306.20 | 309.80 | 306.00 | 6,520 | |
| 307.60 | -2.80 | -0.9% | 305.00 | 323.90 | 299.00 | 9,856 | |
| 310.40 | -7.80 | -2.5% | 313.50 | 319.50 | 299.00 | 13,753 | |
| 318.20 | +8.20 | +2.6% | 311.00 | 318.20 | 311.00 | 375 | |
| 310.00 | -10.00 | -3.1% | 320.10 | 325.00 | 309.00 | 16,081 | |
| 320.00 | -21.00 | -6.2% | 338.20 | 338.20 | 320.00 | 40,563 | |
| 341.00 | +11.00 | +3.3% | 341.00 | 341.00 | 341.00 | 293 | |
| 330.00 | -0.80 | -0.2% | 330.80 | 340.90 | 330.00 | 3,940 | |
| 330.80 | +1.40 | +0.4% | 330.00 | 340.70 | 330.00 | 2,276 | |
| 329.40 | -11.40 | -3.3% | 340.80 | 340.80 | 325.00 | 8,363 | |
| 340.80 | -0.50 | -0.1% | 341.30 | 341.30 | 330.10 | 2,015 | |
| 341.30 | -5.30 | -1.5% | 345.50 | 345.50 | 336.00 | 2,076 | |
| 346.60 | +11.80 | +3.5% | 334.80 | 349.90 | 333.00 | 1,775 | |
| 334.80 | -6.60 | -1.9% | 339.30 | 356.00 | 332.00 | 9,886 | |
| 341.40 | -10.10 | -2.9% | 349.90 | 366.90 | 335.00 | 23,481 | |
| 351.50 | +3.50 | +1.0% | 345.30 | 360.00 | 345.00 | 10,709 | |
| 348.00 | +5.80 | +1.7% | 348.90 | 349.00 | 340.30 | 25,155 | |
| 342.20 | -5.90 | -1.7% | 349.70 | 359.40 | 342.00 | 7,326 | |
| 348.10 | +6.60 | +1.9% | 351.80 | 360.00 | 346.30 | 18,422 | |
| 341.50 | -1.50 | -0.4% | 340.80 | 360.00 | 340.40 | 4,421 | |
| 343.00 | -9.00 | -2.6% | 364.90 | 364.90 | 343.00 | 40,554 | |
| 352.00 | -22.00 | -5.9% | 370.50 | 380.00 | 348.00 | 55,071 | |
| 374.00 | -2.40 | -0.6% | 355.00 | 380.00 | 348.00 | 51,563 | |
| 376.40 | +12.80 | +3.5% | 364.80 | 383.80 | 364.80 | 27,035 | |
| 363.60 | -40.20 | -10.0% | 390.00 | 390.00 | 362.00 | 98,699 | |
| 403.80 | -86.60 | -17.7% | 495.10 | 699.00 | 399.80 | 228,292 | |
| 490.40 | -24.50 | -4.8% | 507.00 | 517.90 | 490.00 | 10,044 | |
| 514.90 | +8.80 | +1.7% | 507.70 | 529.00 | 498.00 | 5,926 | |
| 506.10 | -9.50 | -1.8% | 515.60 | 529.00 | 506.00 | 5,303 | |
| 515.60 | -1.60 | -0.3% | 506.00 | 535.00 | 505.50 | 8,039 | |
| 517.20 | +8.20 | +1.6% | 515.20 | 538.90 | 506.00 | 1,899 | |
| 509.00 | -2.00 | -0.4% | 511.00 | 547.90 | 509.00 | 3,572 | |
| 511.00 | -26.20 | -4.9% | 537.20 | 548.90 | 511.00 | 13,744 | |
| 537.20 | +6.50 | +1.2% | 537.20 | 544.50 | 537.20 | 183 | |
| 530.70 | -2.20 | -0.4% | 532.90 | 544.90 | 510.10 | 1,157 | |
| 532.90 | +22.90 | +4.5% | 531.10 | 540.40 | 520.00 | 4,131 |
Splits
2 splits since 2013 · TASE:CANF · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-3000 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- TASE:CANF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TASE
- Currency
- ILA
What changed lately
Latest news
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Sep 8, 2026
Closed 352.00 (-5.9%) on Sep 8, 2026
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 18, 2026
Closed 500.40 (-3.6%) on May 18, 2026
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
May 13, 2026
Closed 514.80 (+5.1%) on May 13, 2026
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Apr 30, 2026
Closed 507.00 (+10.2%) on Apr 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Mar 30, 2026
Closed 511.80 (-2.2%) on Mar 30, 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Mar 26, 2026
Closed 511.10 (-0.7%) on Mar 26, 2026
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Mar 17, 2026
Closed 570.90 (-1.9%) on Mar 17, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Mar 4, 2026
Closed 762.00 (-49.2%) on Mar 5, 2026
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
Feb 17, 2026
Closed 712.00 (+4.7%) on Feb 17, 2026
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Feb 9, 2026
Closed 674.80 (+2.1%) on Feb 9, 2026
Can-Fite BioPharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 36 in all · newest Sep 8, 2026 · oldest 2025
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 30, 2020
- Decks
- 13 decks · latest November 2025
Where Can-Fite BioPharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:CANF · Home listing · This page | TASE | Israel | ILA |
| NYSE American:CANF | NYSE American | United States | USD |
| BOATS:CANF | BOATS | United States | USD |
Valuation
EV/sales −5.3× against a median of 8.2×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 19, 2026
- Enterprise value
- −7.17M ILS
- P/E
- Loss
- EV/sales
- −5.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Can-Fite BioPharma Ltd. · TASE:CANF | US$4.86M | −US$2.14M | n/a | −5.3× | n/a | 1.0× | n/a | 0.0× | n/a |
| Rakovina Therapeutics Inc · TSXV:RKV | US$5.10M | US$7.20M | n/a | n/a | n/a | n/a | n/a | n/a | -0.43 |
| StimCell Energetics Inc. · OTC:STME | US$5.10M | US$5.09M | n/a | n/a | n/a | n/a | n/a | n/a | 0.99 |
| Longeveron Inc. · NASDAQ:LGVN | US$5.05M | −US$1.78M | n/a | −1.5× | n/a | 1.1× | n/a | 0.1× | 1.55 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Patrys Limited · ASX:PAB | US$4.96M | US$4.47M | n/a | 8.2× | n/a | 10.2× | −363.7% | 0.0× | n/a |
| Invex Therapeutics Ltd. · ASX:IXC | US$4.86M | US$2.20M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Zenith Capital Corporation · OTC:ZHCLF | US$4.83M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.06 |
| NFL Biosciences SA · EURONEXT:ALNFL | US$4.71M | US$5.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TheraCryf PLC · LSE:TCF | US$4.64M | US$2.63M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Pulmatrix, Inc. · NASDAQ:PULM | US$4.64M | US$3.24M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.33 |
| Median of the others | US$4.91M | US$4.47M | 0.8× | 8.2× | 0.9× | 1.6× | −363.7% | 0.0× | 0.33 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.00 ILA · Analysts' mean
- EPS, year to Dec 2026
- -3.02 · 1 analyst
- Revenue, year to Dec 2026
- 404K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Guy Regev | Chief Executive Officer |
| Motti Farbstein | CEO, CFO |
| Yossi Bornstein | CEO |
| Sari Fishman | Vice President of Business Development |
| Pnina Fishman | Executive Chairperson, CSO |
Board
| Director | Role |
|---|---|
| Pnina Fishman | Executive Chairperson, CSO |
| Abraham Sartani | Member of the Board of Directors |
| Guy Regev | Chief Executive Officer |
| Yossi Bornstein | CEO |
Events
Calls
| Call | When | Status |
|---|---|---|
| Can-Fite BioPharma (TASE:CANF) Q3 2020 Earnings Call | Mon, Nov 30, 2020 · 9:15 AM ET | Replay |
Results days
| Quarter | Results |
|---|---|
| Q4 2023 | Mar 28, 2024 · Before open |
| Q3 2023 | Nov 30, 2023 · Before open |
| Q2 2023 | Aug 31, 2023 · Before open |
| Q3 2022 | Nov 25, 2022 · Before open |
| Q3 2021 | Nov 26, 2021 · Before open |
| Quarter to Jun 30, 2021 | Aug 26, 2021 · Before open |
| Quarter to Dec 31, 2020 | Mar 25, 2021 · Before open |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 29 slides | November 2025 |
| Investor Presentation (February 2025) | Investor deck | 23 slides | Feb 5, 2025 |
| Investor Presentation (September 2023) | Investor deck | 22 slides | Sep 7, 2023 |
| Investor Presentation (March 2020) | Investor deck | 20 slides | Mar 9, 2020 |
| Investor Presentation (September 2019) | Investor deck | 19 slides | Sep 6, 2019 |
| Investor Presentation (February 2019) | Investor deck | 19 slides | Feb 1, 2019 |
| Investor Presentation (September 2017) | Investor deck | 22 slides | Sep 8, 2017 |
| Investor Presentation (January 2017) | Investor deck | 20 slides | Jan 6, 2017 |
| Investor Presentation (January 2016) | Investor deck | 21 slides | Jan 11, 2016 |
| Investor Presentation (September 2015) | Investor deck | 22 slides | Sep 9, 2015 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2015) | Investor deck | 23 slides | May 29, 2015 |
| Investor Presentation (July 2014) | Investor deck | 20 slides | Jul 8, 2014 |
| Investor Presentation (October 2013) | Investor deck | 20 slides | Oct 31, 2013 |
Financings
| Raise | Date |
|---|---|
| Warrant exercise of american Depositary Shares upon exercise of warrants Announced: about US$4M · US$5 a share · Warrants at US$5 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes | Mar 4, 2026 |
| Public offering of american Depositary Shares (or pre-funded warrants) with short-term warrants Announced: about US$5M · US$0.6 a share · Warrants at US$0.6 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes | Jul 28, 2025 |
| Registered direct offering of american Depositary Shares Announced: US$3M · US$1.2 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Research and development, clinical trials, working capital and general corporate purposes | Apr 14, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405.0K | 674.0K | 743.0K | 810.0K | 853.0K | 763.0K | 2.03M | 3.82M | 789.0K | 169.5K |
| Cost of revenue | 26.0K | 0 | 0 | 0 | ||||||
| Gross profit | 412.4K | 674.0K | 743.0K | 810.0K | 853.0K | 763.0K | 2.03M | 3.82M | 844.7K | 169.5K |
| Research and development | 6.69M | 5.76M | 5.98M | 7.76M | 9.85M | 12.0M | 11.0M | 6.08M | 5.11M | 6.12M |
| Selling, general and administrative | 3.66M | 3.05M | 2.96M | 263.0K | 466.0K | 317.0K | 3.06M | 3.16M | 2.92M | 2.70M |
| Operating income | -9.95M | -8.13M | -8.20M | -10.1M | -12.8M | -14.1M | -12.0M | -5.41M | -7.18M | -8.63M |
| Depreciation and amortization | 24.0K | 7.00K | 15.0K | 14.0K | 14.0K | 12.0K | 14.0K | 14.0K | 19.0K | 18.5K |
| EBITDA | -9.93M | -8.12M | -8.18M | -10.1M | -12.8M | -14.1M | -12.0M | -5.40M | -7.17M | -8.62M |
| Interest expense | 284.0K | 291.0K | 506.0K | -222.0K | 18.0K | 363.0K | 427.0K | 1.20M | 1.10M | 27.3K |
| Income before tax | -9.83M | -7.88M | -7.63M | -10.2M | -12.6M | -14.4M | -12.6M | -6.57M | -4.81M | -6.99M |
| Income tax | 360.0K | -20.0K | 427.0K | 4.00K | 29.0K | 29.1K | ||||
| Net income | -9.83M | -7.88M | -7.63M | -10.2M | -12.6M | -14.4M | -12.6M | -6.57M | -4.84M | -8.39M |
| Earnings per share, basic | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 | -0.04 | -0.14 | -0.17 | -0.14 | -0.21 |
| Earnings per share, diluted | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 | -0.04 | -0.14 | -0.17 | -0.14 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.53M | 4.83M | 4.28M | 2.98M | 4.39M | 8.27M | 2.70M | 3.62M | 3.50M | 8.12M |
| Short-term investments | 1.00K | 5.00K | 19.0K | 8.00K | 237.0K | 75.0K | 64.0K | 273.0K | ||
| Receivables | 74.0K | 47.0K | 48.0K | 18.0K | 637.0K | 41.0K | 66.0K | 21.8K | ||
| Inventory | -39.0K | -48.0K | -715.0K | -3.97M | -3.30M | |||||
| Current assets | 9.44M | 8.98M | 9.91M | 9.16M | 20.1M | 9.40M | 7.14M | 7.90M | 6.87M | 10.1M |
| Property, plant and equipment | 5.00K | 27.0K | 29.0K | 42.0K | 47.0K | 50.0K | 36.0K | 47.0K | 28.0K | 40.0K |
| Total assets | 9.51M | 9.12M | 9.99M | 9.28M | 20.3M | 9.52M | 8.17M | 7.95M | 7.83M | 10.2M |
| Accounts payable | 1.16M | 618.0K | 427.0K | 896.0K | 954.0K | 561.0K | 2.16M | 1.07M | 427.0K | 1.25M |
| Current liabilities | 2.73M | 2.05M | 2.02M | 2.50M | 2.73M | 1.27M | 3.27M | 3.12M | 1.80M | 2.50M |
| Total debt | 71.0K | 104.0K | 40.0K | 62.0K | 124.0K | 67.0K | 75.0K | |||
| Total liabilities | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M | 3.45M | 5.73M | 4.94M | 4.78M | 6.29M |
| Shareholders' equity | 5.59M | 5.44M | 6.24M | 4.47M | 14.4M | 6.07M | 2.44M | 3.02M | 2.98M | 3.91M |
| Shares outstanding | 2.62M | 994.4K | 1.36B | 815.7M | 815.7M | 463.8M | 120.7M | 40.4M | 463.8M | 40.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.95M | -7.64M | -8.44M | -10.8M | -9.86M | -12.1M | -11.1M | -4.16M | -8.97M | -8.93M |
| Capital spending | -2.00K | -5.00K | -2.00K | -9.00K | -11.0K | -26.0K | -3.00K | -33.0K | -7.00K | -10.4K |
| Free cash flow | -8.95M | -7.64M | -8.44M | -10.8M | -9.87M | -12.1M | -11.1M | -4.19M | -8.98M | -8.94M |
| Cash from investing | -2.00K | 1.50M | 498.0K | 9.50M | -14.5M | -26.0K | -3.00K | -33.0K | -29.0K | -10.4K |
| Cash from financing | 9.64M | 6.71M | 9.14M | 6.53M | 20.5M | 17.7M | 10.2M | 4.39M | 4.47M | 0 |
| Dividends paid | -2.59M | -715.0K | ||||||||
| Share buybacks | 17.0M | 17.0M | ||||||||
| Change in cash | 703.0K | 547.0K | 1.30M | -1.41M | -3.88M | 5.57M | -918.0K | 110.0K | -4.61M | -9.05M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 2, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 26, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 13, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 9, 2026 | Offer document | SEC |
| F-3 · Registration statement | Sep 28, 2026 | Offer document | SEC |
| F-3/A · Registration statement, amended | Sep 25, 2026 | Offer document | SEC |
Show 200 filings
This page holds 200 of 868 filings. Open Filings
Cap table
Built by 6ix from Can-Fite BioPharma Ltd.’s releases · as of Mar 4, 2026
- Common shares
- 6,063,093
- Fully diluted
- 6,063,093
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 6,063,093 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 6,063,093 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Guy Regev Other companies: Big Digital Energy, Inc. (Director · Nov 21, 2011 – Mar 18, 2012 · Past) | Chief Executive Officer · Since at least Mar 18, 2026 |
| Yoseph Bornstein Other companies: Microbot Medical Inc. (Director · Nov 28, 2016 – Nov 2, 2023 · Past) | Director · Since at least Mar 18, 2026 |
| Abraham Sartani | Member of the Board of Directors · Since at least Nov 6, 2026 |
| Ilan Tamir | Since at least Nov 6, 2026 |
| Motti Farbstein | CEO, CFO and COO · Since at least Mar 18, 2026 |
| Pnina Fishman | Executive Chairperson, CSO · Since at least Mar 18, 2026 |
| Sari Fishman | Vice President of Business Development · Since at least Mar 18, 2026 |
| Yossi Bornstein | CEO · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Can-Fite BioPharma Ltd.